Objective: To assess the long-term outcome of lupus nephritis in children with systemic lupus erythematosus followed up over 12 years at a tertiary care teaching hospital in Eastern India.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disorder that manifests as a chronic inflammatory disorder with multisystem involvement. The presentation is highly variable, the disease follows a relapsing and remitting course, and although standardized treatment has improved the short-and medium-term outlook, long-term prognosis remains poor in children with lupus with major organ involvement (1). Lupus has a higher incidence of renal involvement in children than in adults (2) (3) (4) . Lupus nephritis is seen in nearly 50% patients with pediatric-onset SLE (pSLE), which may manifest as asymptomatic urinary findings, acute kidney injury, and even chronic renal disease (5) . Renal involvement remains one of the important factors influencing management and long-term prognosis of pSLE (6) (7) (8) (9) . There is some evidence that the prognosis of lupus nephritis in developing countries is worse than that in developed countries (10) . Some studies from other parts of India have highlighted the long-term outcome in children with lupus nephritis (11, 12) , but there has been no detailed report from Eastern India.
This study aimed to evaluate the long-term outcome of lupus nephritis in pSLE followed up over 12 years at a tertiary care teaching hospital in Eastern India. The outcome of half these children with 8 years of follow-up has been previously reported (13) .
Material and Methods
Patient selection A retrospective observational study was conducted with follow-up data on pSLE from the pediatric rheumatology clinic collected over the past 12 years from in the institute concerned. The study was conducted in accordance to the guidelines of the Institutional Ethics Committee for human research. As it was a retrospective study, requirement for informed consent was waived. Children with SLE, defined according to the American College of Rheumatology (ACR) 1997 revised criteria, who developed lupus nephritis in due course or presented with lupus nephritis within 12 years of age were included (14) (15) (16) and outcome were collected. For the analysis of short-term outcomes, children were classified into those with complete (CR) remission, partial remission (PR), active disease or no response, and progression to ESRD (those requiring renal replacement therapy). For survival analysis, time till death (actuarial survival) and time till ESRD (renal survival) were assessed. In cases of death, the cause of death was noted.
Therapy
Depending on renal biopsy findings, therapy was decided according to the ACR guidelines (14) . Various activity and chronicity indices were considered while selecting the available therapy options. Oral hydroxychloroquine (5-10 mg/kg/day) were administered to all pSLE patients, unless contraindicated, since 2008 as per recommendations (17) . Angiotensin-converting enzyme inhibitors were the preferred first line antihypertensive, wherein renal function was preserved. For comparative analysis, treatment modalities were categorized into four groups, arm 1 being prednisolone only, arm 2 being prednisolone and cyclophosphamide, arm 3 being prednisolone and azathioprine, and arm 4 being prednisolone and mycophenolate mofetil.
Response to therapy, as guided by ACR criteria, was defined as CR, PR, nonresponse or progression of active disease (NR/P), and ESRD. Indications of renal biopsy were also in accordance to the ACR guidelines.
Analysis
Statistica version 6 (StatSoft Inc.; Tulsa, OK, USA) and MedCalc version 11.6 (MedCalc Software; Mariakerke, Belgium) were used for statistical analysis. Normally distributed numerical variables were expressed as mean and standard deviation (SD), whereas numerical variables when skewed were expressed as median and interquartile range (IQR). Numerical variables were tested for normal distribution by Kolmogorov-Smirnov Goodness-of-Fit test. Mortality was compared among the different lupus classes and therapy groups with Kaplan-Meier analysis and log-rank test. Two-tailed p<0.05 was considered statistically significant.
Results
Over 12 years, a total of 78 children were diagnosed with pSLE, of which 46 developed lupus nephritis, giving an incidence of 58.97% (95% CI 48.06%-59.89%). The age at onset of lupus nephritis was 10.2±2.43 years (mean±SD) with the range of 5.5-14.5 years. The median duration of the follow-up (n=46) was 90 months (IQR 70.5-108 months). The basic demographic and clinical profile of the subjects is shown in Table 1 .
Majority of children presented with lupus nephritis at onset (82.61%), whereas the rest developed at a later date. Of the children who underwent renal biopsy, majority belonged to class IV (30.43%) followed by class II and then class III.
The commonest presenting feature of lupus nephritis was oliguria with anasarca (13/46; 28.26%), and the commonest laboratory abnormality was proteinuria with hematuria (14/46; 30.43%) as depicted in Table 2 .
Among extrarenal manifestations, hematological abnormalities were the commonest, followed by serosal and neurological manifestations. Of the hematological manifestations, autoimmune hemolytic anemia was the commonest followed by immune thrombocytopenic purpura and antiphospholipid antibodies (APLA). The latter presented as recurrent thrombosis, cerebrovascular accidents, and acute renal failure, which were fatal. Incidence of neuropsychiatry SLE (NPSLE) in boys was significantly higher than that in girls (p=0.005). Headache was the commonest manifestation of NPSLE, followed by seizures and behavioral abnormalities. Regarding serosal involvement, joints followed by pleura and peritoneum were affected. Among cardiovascular involvement, three newborns had second degree heart block, one had pericardial effusion as a part of the flare-up of disease activity, and one developed congestive heart failure secondary to SLE myocarditis.
Of the four treatment options, 11 children received arm 1 therapy, 21 arm 2, 8 arm 3, and Differences in mortality were not significant among the different lupus classes (Figure 1 ) and therapy groups ( Figure 2 ) using survival analysis techniques (p=0.860 and 0.630, respectively). Because of limited numbers, median survival could be estimated only for lupus class II and therapy arm 2 (138 months).
Comparison of ESRD between lupus classes and therapy groups showed a similar pattern (Table 3) . Again, because of limited numbers, median time till ESRD development could not be estimated in individual subgroups.
Discussion
The incidence of lupus nephritis found to be 58.8% in our study is comparable with those of other recent Indian and western studies (8-10, 12, 19) . A small increase in incidence of nephritis is noted from 54.7% as reported from our institution in 2012 to the current 58.8%. There has also been an increase in the proportion of children with lupus nephritis who underwent biopsy (13/23 in the 2012 report against 41/46 in the current report) (13) . This might be attributed to the growing awareness of lupus nephritis among doctors who aggressively look for evidence of nephritis by clinical and laboratory evaluation. Although greater proportion of girls was affected by lupus nephritis, boys were found to have a poorer prognosis. A similar observation was made by Hari et al. (19) that more boys were found to be affected with stage IV nephritis. The clinical and laboratory features of lupus nephritis encountered in our study are broadly in conformity with other reports (20) (21) (22) (23) . It has been the classical textbook teaching that SLE results in non-erosive arthritis; however, we found two children with deforming arthritis satisfying the rhupus syndrome designation and one with SLE and cutaneous scleroderma overlap syndrome (24, 25) . Neuropsychiatric involvement in SLE can be severe and troubling, greatly influencing the quality of life and disease outcome. The expressions can be complex with central, peripheral, and autonomous nervous systems affected (26) . Central nervous system symptoms were encountered in 28.26% cases in our series. Relevant immunological markers were encountered in the majority of cases, with nearly 98% positive for antinuclear antibodies. Previous studies revealed that those who present at a younger age with severe nephritis and nervous system affections have poorer prognosis (2, 27) .
At 17.39%, mortality in our study was between what has been observed in various other studies and higher than the 8.2% observed in a large Indian series with a 25-year follow-up (4, 11, (28) (29) (30) (31) . However, no significant difference in mortality was observed in different lupus nephritis classes or therapy arm groups. Septicemia occurring on a background of ESRD or otherwise was the commonest cause of death (75%). Other previous Indian studies and studies from other developing countries (Table  4) have also reported a similar trend wherein most children with lupus nephritis succumbed to serious infections (11, 18, (31) (32) (33) (34) .
Of the five children who developed ESRD, three succumbed to serious sepsis, and among them, one was on continuous ambulatory peritoneal dialysis and had undergone a change in the therapy arm for severe disease. The other two children however could not afford renal replacement therapy and were lost to follow-up. This poor outcome in children with ESRD highlights the constraints faced by caregivers and merits the establishment of support groups for children with lupus in developing countries such as ours.
The institution in which the study was performed serves as an apex referral center in the government sector, and patients from all over the state and neighboring states are referred to our pediatric rheumatology clinic with provisional diagnosis or suspicion of SLE for further work-up, management, and follow-up. We therefore had the advantage of a large catchment area. However, this study also has its share of limitations. Maintenance of patient records and follow-up data was a tedious procedure in the absence of fully computerized medical records, but this could largely be overcome with diligence and cooperation among treating physicians. Renal biopsy could not be performed in all nephritis patients owing to financial constraints in some and lack of consent in others. Use of biologicals, although indicated, was seldom encountered in our series due to the lack of affordability.
In conclusion, this study enlightens us about various aspects of lupus nephritis and their outcome patterns in children from developing countries such as India. Further studies are required to assess the effectiveness of existing and new treatment options and their impact on long-term disease outcome in these resource-poor setting.
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